Copertina

Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single‐center experience

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Xiao He, Duanfeng Jiang, Liang Zhao, Shuping Chen, Yan Zhu, Qun He, Yanjuan He
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Cancer Medicine
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
di: Xiaoyan Han, et al.
Pubblicazione: (2024)

Infections associated with CAR ‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
di: Jing An, et al.
Pubblicazione: (2024)

TP53 and KMT2D mutations associated with worse prognosis in peripheral T‐cell lymphomas
di: Lingling Wang, et al.
Pubblicazione: (2024)

Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors
di: Shizhe Li, et al.
Pubblicazione: (2024)

Angiogenesis and multiple myeloma: Exploring prognostic potential of adrenomedullin
di: Angelos Giannakoulas, et al.
Pubblicazione: (2024)

“They don't care to study it”: Trust, race, and health care experiences among patient‐caregiver dyads with multiple myeloma
di: Shakira J. Grant, et al.
Pubblicazione: (2024)

The role of programmed cell death in osteosarcoma: From pathogenesis to therapy
di: Suqing Liu, et al.
Pubblicazione: (2024)

Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma
di: Xi‐xi Yin, et al.
Pubblicazione: (2024)

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
di: Danilo De Novellis, et al.
Pubblicazione: (2024)

Biomarkers of peripheral blood neutrophil extracellular traps in the diagnosis and progression of malignant tumors
di: Min Wang, et al.
Pubblicazione: (2024)

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
di: Anna Furlan, et al.
Pubblicazione: (2024)

An individualized stemness‐related signature to predict prognosis and immunotherapy responses for gastric cancer using single‐cell and bulk tissue transcriptomes
di: Linyong Zheng, et al.
Pubblicazione: (2024)

miR‐34a promotes the immunosuppressive function of multiple myeloma‐associated macrophages by dampening the TLR‐9 signaling
di: Rui Zhang, et al.
Pubblicazione: (2024)

A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China
di: Yanqiu Xiong, et al.
Pubblicazione: (2024)

Clinical factor‐based risk stratification for precision therapy in locally advanced squamous cell carcinoma of the uterine cervix
di: Feng‐Yuan Liu, et al.
Pubblicazione: (2024)

Deletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non‐metastatic stage T4 nasopharyngeal carcinoma in IMRT era
di: Yuming Zheng, et al.
Pubblicazione: (2024)

Schizandrin A induces non‐small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation
di: Linhai Zhu, et al.
Pubblicazione: (2024)

The quantitative parameters based on marrow metabolism derived from synthetic MRI: A pilot study of prognostic value in participants with newly diagnosed multiple myeloma
di: Sha Cui, et al.
Pubblicazione: (2024)

Advances in research on factors affecting chimeric antigen receptor T‐cell efficacy
di: Delian Zhou, et al.
Pubblicazione: (2024)

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
di: Alice Sýkorová, et al.
Pubblicazione: (2024)

Comparison of percutaneous ablation and hepatectomy for liver metastasis: A single center retrospective study
di: Seiichi Tawara, et al.
Pubblicazione: (2024)

Establishing a robust radioligand therapy program: A practical approach for North American centers
di: Erik S. Mittra, et al.
Pubblicazione: (2024)

Exploring the factors affecting the occurrence of postoperative MVI and the prognosis of hepatocellular carcinoma patients treated with hepatectomy: A multicenter retrospective study
di: Jilin Yang, et al.
Pubblicazione: (2024)

Anti‐tumorigenic effects of naive and TLR4‐primed adipose‐derived mesenchymal stem cells on pancreatic ductal adenocarcinoma cells
di: Demet Kaçaroğlu, et al.
Pubblicazione: (2024)

Obesity enhances the response to neoadjuvant anti‐ PD1 therapy in oral tongue squamous cell carcinoma
di: Xiyan Tan, et al.
Pubblicazione: (2024)

Metformin Inhibits the Progression of Pancreatic Cancer Through Regulating miR‐378a‐3p/VEGFA/RGC‐32 Axis
di: Jinli He, et al.
Pubblicazione: (2024)

Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy
di: Guangyang Weng, et al.
Pubblicazione: (2024)

Is conventional functional liver remnant volume higher than 40% still sufficient to prevent post‐hepatectomy liver failure in jaundiced patients with hilar cholangiocarcinoma? A single‐center experience in China
di: Tian‐Run Lv, et al.
Pubblicazione: (2024)

Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy
di: Xiuyong Dang, et al.
Pubblicazione: (2024)

Heat shock transcription factor 1 facilitates liver cancer progression by driving super‐enhancer‐mediated transcription of MYCN
di: Yizhe Liu, et al.
Pubblicazione: (2024)

A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after anti‐PD‐1/L1 therapy
di: Yuguang Zhao, et al.
Pubblicazione: (2024)

Are embryonic stem cell markers and ALDH1A1 relevant in the context of breast cancer estrogen positivity?
di: Noha A. Mousa, et al.
Pubblicazione: (2024)

Patient‐reported physical well‐being predicts good long‐term survival of hematopoietic stem cell transplantation
di: Yin Lu, et al.
Pubblicazione: (2024)

Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
di: Yi Li Jiang, et al.
Pubblicazione: (2024)

Trend analysis of hematological tumors in adolescents and young adults from 1990 to 2019 and predictive trends from 2020 to 2044: A Global Burden of Disease study
di: Linlin Huang, et al.
Pubblicazione: (2024)

Predicting Neoplastic Polyp in Patients With Gallbladder Polyps Using Interpretable Machine Learning Models: Retrospective Cohort Study
di: Zhaobin He, et al.
Pubblicazione: (2025)

Low‐dose fluconazole as a useful and safe prophylactic option in patients receiving allogeneic hematopoietic stem cell transplantation
di: Kentaro Hirade, et al.
Pubblicazione: (2024)

Correction to “Are embryonic stem cell markers and ALDH1A1 relevant in the context of breast cancer estrogen positivity”
Pubblicazione: (2024)

Unlocking the Potential of Disulfidptosis‐Related LncRNAs in Lung Adenocarcinoma: A Promising Prognostic LncRNA Model for Survival and Immunotherapy Prediction
di: Xin Nie, et al.
Pubblicazione: (2024)

Association of blood cell‐based inflammatory markers with gut microbiota and cancer incidence in the Rotterdam study
di: Shiva Najjary, et al.
Pubblicazione: (2024)